Results 31 to 40 of about 67,658 (263)

Peripheral blood eosinophilia in dogs: Prevalence and associated diseases

open access: yesVeterinary Medicine and Science, 2022
Background Canine eosinophilia has not been evaluated over the last two decades. As in human local differences, changes in the prevalence and associated diseases over time can be expected.
Abigail Guija‐de‐Arespacochaga   +3 more
doaj   +1 more source

Polydatin alleviates mitochondrial damage and apoptosis of lung epithelial cells by inhibiting toll‐like receptor 4‐dependent macrophage activation in asthma

open access: yesAnimal Models and Experimental Medicine, EarlyView.
The alleviation of asthma by polydatin is dependent on the blockage of the toll‐like receptor 4 (TLR4)/P2X7R synergy in macrophages. The blockage of the TLR4/P2X7R synergy results in decreased release and secretion of interleukin‐1β (IL‐1β) and IL‐18. In epithelial cells, low IL‐1β and IL‐18 levels inhibit mitochondrial damage and apoptosis.
Guangxing Li   +9 more
wiley   +1 more source

Eosinophilia in school-going children with Plasmodium falciparum and helminth infections in the Volta region of Ghana

open access: yesThe Pan African Medical Journal, 2021
INTRODUCTION: Eosinophilia is seen in children infected with parasitic organisms. This study aimed at evaluating eosinophilia in children infected with Plasmodium falciparum, Schistosoma haematobium and intestinal helminths in the Volta Region of Ghana ...
Verner Ndudiri Orish   +9 more
doaj   +1 more source

An Unusual Presentation of Angiolymphoid Hyperplasia with Eosinophilia as Postauricular Mass: A case Report [PDF]

open access: green, 2023
Rubina Galib   +5 more
openalex   +1 more source

Successful treatment of eosinophilia associated with dialysis‐related renal cancer with radical nephrectomy

open access: yesIJU Case Reports
Introduction Secondary eosinophilia due to solid tumors is a rare case. This is the first study to report secondary eosinophilia due to renal cancer in a patient on dialysis. Case presentation A 70‐year‐old man, on long‐term hemodialysis was incidentally
Yuta Goto   +8 more
doaj   +1 more source

Eosinophilia in Very Low Birth Weight Infants

open access: yesPediatrics and Neonatology, 2010
Eosinophilia is common in premature infants, though its clinical significance remains unknown. This study investigated the pattern of eosinophilia and related factors in very low birth-weight (VLBW) infants.
Jui-Mei Yen   +5 more
doaj   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair   +14 more
wiley   +1 more source

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab

open access: yesClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021
Background: Paraneoplastic hyper-eosinophilia associated with metastatic lung adenocarcinoma is a rare finding and has been associated with a poor prognosis when present.
Hisham Wehbe   +2 more
doaj   +1 more source

The challenge of diagnosing and classifying eosinophilia and eosinophil disorders: A review

open access: yesCentral European Journal of Immunology
Eosinophilia is a feature of multiple conditions, both hematologic and non-hematologic, and may be associated with organ damage. The pathogenesis of eosinophilia can follow two distinct pathways.
Agnieszka Szymczyk   +2 more
doaj   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy